Portfolio Alert: HK-Listed CSTONE PHARMA-B Surges 6% on Stock Connect Inclusion and Global Trial Milestones
CSTONE PHARMA-B (02616) witnessed a strong afternoon rally on Tuesday, climbing more than 6% before settling with a 5.27% gain at HK$6.385, backed by robust trading volume of HK$82.09 million. The surge comes amid a wave of positive catalysts and growing institutional confidence in the biotech firm's pipeline and strategic positioning.
The immediate trigger was the company's announcement that its shares listed on the Hong Kong Stock Exchange have been included in the Stock Connect eligible securities list, effective from September 7, 2026. This inclusion is expected to broaden the shareholder base by facilitating mainland capital inflows, a significant liquidity boost for the pharmaceutical developer.
Beyond the listing milestone, CSTONE PHARMA-B is making notable strides in its clinical development programs. The global Phase I/II trials for its flagship PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, are advancing efficiently, with the company on track to initiate the first wave of global Phase III registration trials by the end of 2026. Additionally, the Phase I global study for its self-developed EGFR/HER3 bispecific ADC, CS5007, has been launched, running concurrently in China and Australia.
International financial heavyweights are also aligning behind the company's prospects. Both Jefferies and Goldman Sachs have recently released research reports endorsing CSTONE PHARMA-B, with their optimism anchored on three key factors: the continuously improving clinical data for the core asset CS2009, the substantial business development and out-licensing opportunities on the horizon, and the dense schedule of global Phase III multi-regional clinical trials expected to materialize before year-end. Goldman Sachs further projects that the next 6 to 12 months will be a critical window for the company to deliver a concentrated series of transformative catalysts, reinforcing the positive sentiment surrounding the stock.